A molecular diagnostics products manufacturing company, Seegene has announced the commercial availability of its real-time Anyplex II STI-7 Detection Assay. Based on the TOCE technology, the real-time assay will empower clinicians to help limit the spread of sexually transmitted infections and protect health.
The Anyplex II STI-7 is the only real-time PCR test capable of simultaneously detecting seven of the general causatives of the infection from urine, urethral or vaginal swabs and a cytology specimen. The STI-7 provides a fast, economic and effective screening method for pathogens causing sexually transmitted infections (STI).
The Centers for Disease Control and Prevention has estimated that every year there are 19 million cases with 50% affecting young adults aged between 15 and 24. The US healthcare system spends more than $15.9 billion on STI.
Causal pathogens of STI such as Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma hominis, Mycoplasma genitalium, Ureaplasma urealyticum, Ureaplasma parvum and Trichomonas vaginalis can be detected using the Anyplex II STI-7 Detection assay.
The Chief Executive Officer of Seegene, Dr Jong-Yoon Chun stated that the assay provides an advanced tool to clinicians to enable cost effective, accurate and fast STI diagnoses, thus allowing physicians to make healthcare decisions sooner. This has a positive impact on the patient’s health and on the healthcare system.
The TOCE technology developed by Seegene allows any real-time multiple color PCR instrument to function as a multiplex platform and provides clinicians with consistent Tm values as well as the flexibility to use their existing real-time PCR instruments.
Source: http://www.seegene.com/